Blueberries Medical (BBM) AI Stock Analysis

• Market Cap: C$7.43M
• Dividend Yield: N/A
• Average Volume (3M): 5.76K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.75
• Revenue Growth: 55.74%
• EPS Growth: -27.59%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 495,090,100
• 10 Day Avg. Volume: 100
• 30 Day Avg. Volume: 5,759
• PEG Ratio: 0.06
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 8.46
• P/FCF Ratio: -5.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.02 ▼(-25.00% Downside)

The score is held back primarily by weak financial performance driven by ongoing losses and worsening cash burn, despite a cleaner low-debt balance sheet. Technicals provide some support with price above key moving averages and positive MACD, but overbought RSI/Stoch conditions temper the outlook. Valuation is constrained by negative earnings and no dividend support.

Positive Factors

Improved gross margin (~31% TTM)

A sustained gross margin near 31% indicates meaningful improvement in unit economics for cultivation and formulations. Over 2–6 months this supports variable-cost coverage, gives management margin leverage as revenue scales, and increases the realistic path to operating leverage if SG&A is controlled.

Minimal total debt / low leverage

Very low leverage reduces insolvency and interest-cost risk, preserving flexibility to fund operations or capex through equity or low-cost financing. This durable balance sheet strength extends the company’s runway while it works to moderate cash burn or pursue strategic investments.

Historic revenue expansion (2020–2024)

Material top-line expansion through 2024 demonstrates sustainable market demand and commercial execution across cultivation, formulations, and channels. A prior ability to scale revenue is a durable indicator the business model can grow given distribution and product-market fit.

Negative Factors

Large operating losses / widening net loss

Persistent, large operating losses and a widening net loss are structural threats to equity value and reinvestment capacity. Over months this erodes retained capital, pressures management to cut investment or raise dilutive capital, and delays sustainable profitability.

Consistently negative operating cash flow

Ongoing negative operating cash flow and worsening cash burn force reliance on external financing or balance-sheet draws. This raises medium-term liquidity and refinancing risk, constrains strategic flexibility, and can increase financing costs or dilution until operations generate positive cash.

Declining equity and negative ROE

Falling equity and assets alongside sharply negative ROE signal value erosion from losses. Over a 2–6 month horizon this undermines capital resilience, limits borrowing capacity despite low nominal debt, and indicates the firm must restore profitability to halt balance-sheet deterioration.

Blueberries Medical Business Overview & Revenue Model

Company Description

Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquartered in Bogotá, Colombia.

How the Company Makes Money

Blueberries Medical generates revenue primarily through the sale of its medical cannabis products to licensed distributors, pharmacies, and healthcare providers. The company has established key revenue streams from its cultivation operations, where it produces high-quality cannabis that is sold in bulk. Additionally, BBM generates income from its proprietary formulations and branded products, which are marketed directly to consumers through online platforms and retail partnerships. The company also benefits from strategic partnerships with healthcare institutions and research organizations, enabling it to explore new therapeutic applications and expand its market reach. Furthermore, BBM may engage in licensing agreements for its intellectual property, diversifying its income sources.

Blueberries Medical Financial Statement Overview

Summary

Despite improved gross margin and very low debt, the company remains dominated by large operating losses and a widening net loss in TTM, with consistently negative operating cash flow and free cash flow that worsened versus 2024.

Income Statement

Revenue scaled up materially from 2020 to 2024, but TTM (Trailing-Twelve-Months) revenue slipped versus the prior year. Gross margin improved dramatically versus the early years and remains positive (about 31% in TTM), showing better unit economics. However, profitability is still very weak: operating losses remain large and the net loss widened in TTM, with net margins deeply negative, indicating the company has not yet converted growth into sustainable earnings.

Balance Sheet

Leverage has improved substantially: total debt is minimal in the latest periods and debt relative to equity is very low in both 2024 and TTM (roughly 1%–2%), reducing financial risk. That said, equity and total assets have trended down meaningfully since 2023, and returns on equity remain sharply negative, reflecting continued value erosion from ongoing losses.

Cash Flow

Cash generation is a key pressure point: operating cash flow and free cash flow are consistently negative across all periods, and TTM (Trailing-Twelve-Months) cash burn worsened versus 2024. While cash outflow broadly tracks reported losses (cash flow to net income is ~1x), the business is still funding operations through external capital or balance-sheet resources, keeping liquidity and financing risk elevated until cash burn moderates.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	413.97K	471.41K	288.27K	235.45K	138.75K	65.98K
Gross Profit	128.09K	164.52K	84.22K	-17.72K	-245.45K	62.40K
EBITDA	-1.44M	-1.04M	-1.22M	-811.47K	-4.05M	-4.11M
Net Income	-1.55M	-1.15M	-1.64M	-1.47M	-5.15M	-4.94M
Balance Sheet
Total Assets	1.18M	1.38M	2.42M	3.35M	3.59M	7.27M
Cash, Cash Equivalents and Short-Term Investments	23.81K	66.08K	818.16K	1.41M	1.34M	306.51K
Total Debt	11.02K	11.44K	12.80K	1.34M	1.44M	1.49M
Total Liabilities	409.76K	545.61K	470.72K	1.89M	2.16M	3.38M
Stockholders Equity	766.98K	834.81K	1.95M	1.47M	1.43M	3.89M
Cash Flow
Free Cash Flow	-1.31M	-796.85K	-1.35M	-1.47M	-1.73M	-3.00M
Operating Cash Flow	-1.31M	-796.85K	-1.33M	-1.47M	-1.68M	-2.39M
Investing Cash Flow	-3.76K	9.00K	382.92K	101.94K	-48.77K	-611.04K
Financing Cash Flow	1.05M	-1.95K	539.10K	1.35M	2.77M	783.92K

Blueberries Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.07 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BBM	49 Neutral	C$7.43M	-4.05	-150.44%	―	55.74%	-27.59%
MVMD	42 Neutral	C$5.29M	-0.47	-148.48%	―	-46.59%	8.26%
CDVA	41 Neutral	C$2.20M	-0.76	―	―	1.60%	-213.10%
AYUR	40 Underperform	C$973.52K	-0.67	-271.33%	―	15.95%	-1.81%